CSI Market
Sign In | Register

Eli Lilly (LLY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LLY Annual Cash Flow →
Reviewing cash flow figures over time highlights how Eli Lilly balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income14,491.00
Depreciation & amortization1,043.00
Amortization of Other Assets0.00
Write-down of identifiable intangibles0.00
Accountig change0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
Minority Interests0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation362.00
Stockbased compensation0.00
Gains (Losses) on Extinguishment of Debt0.00
Acquired In Process Research And Development Net Of Tax-
Research And Development Asset Acquired Other Than Through Business Combination Written Off584.00
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts and Other Receivables0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Accrued expenses0.00
Postretirement benefits0.00
Increase (Decrease) in Deferred Income Taxes433.00
Other Working Capital2,334.00
Other assets & liabilities0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2,640.00
Discontinued operations0.00
Net Cash flow from Operating Activities16,023.00
Investing Activities
Capital Expenditures-5,259.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term investments acq.0.00
Proceeds from other investments0.00
Purchase Of In Process Research And Development-
Purchased In Process Research And Development-
Purchases Of In Process Research And Development-
Increase (Decrease) in Restricted Cash0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Payments to Acquire Other Investments-604.00
Purchases of Long-term assets0.00
Acquisition Net of Cash Acquired6,319.00
Investment in affiliate0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities-158.00
Other Net-19,610.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-19,312.00
Financing Activities
Short-term debt Net5,284.00
Other borrowing transactions0.00
Long-term debt - borrowings8,941.00
Long-term debt - repayments-1,623.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock-3,957.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net-595.00
Other net0.00
Proceeds from Issuanceor Sale of Equity from Subsidiary-
Dividends paid to minority interests0.00
Dividends paid-3,094.00
Net Cash Flow from Financing Activities4,956.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow10,764.00
Total Cash Flow1,682.00
4 historic quarters locked

Sign in to unlock the full Eli Lilly cash flow history.

Sign In Create Free Account

About Eli Lilly and Co Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 5, 2026
  • Source: lly-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000059478-26-000081

Figures are derived from filed reports and may be restated. Historical data is subject to revision.